BioCryst Downgraded By JPMorgan, Analysts Await 'More Data'
JPMorgan Reiterates Overweight On Medicines Co, Sees $50 Per Share On DCF Basis
JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition'
Warner Chilcott is JP Morgan's Top Pick Within Specialty Pharmaceuticals (WCRX)